» Articles » PMID: 34138458

A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine

Overview
Specialty Pharmacology
Date 2021 Jun 17
PMID 34138458
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19) vaccine in the province of Alberta, Canada.

Methods: We developed an epidemiologic model to evaluate allocation strategies defined by age and risk target groups, coverage, effectiveness and cost of vaccine. The model simulated hypothetical immunisation scenarios within a dynamic context, capturing concurrent public health strategies and population behavioural changes.

Results: In a scenario with 80% vaccine effectiveness, 40% population coverage and prioritisation of those over the age of 60 years at high risk of poor outcomes, active cases are reduced by 17% and net monetary benefit increased by $263 million dollars, relative to no vaccine. Concurrent implementation of policies such as school closure and senior contact reductions have similar impacts on incremental net monetary benefit ($352 vs $292 million, respectively) when there is no prioritisation given to any age or risk group. When older age groups are given priority, the relative benefit of school closures is much larger ($214 vs $118 million). Results demonstrate that the rank ordering of different prioritisation options varies by prioritisation criteria, vaccine effectiveness and coverage, and concurrently implemented policies.

Conclusions: Our results have three implications: (i) optimal vaccine allocation will depend on the public health policies in place at the time of allocation and the impact of those policies on population behaviour; (ii) outcomes of vaccine allocation policies can be greatly supported with interventions targeting contact reduction in critical sub-populations; and (iii) identification of the optimal strategy depends on which outcomes are prioritised.

Citing Articles

A novel comparison framework for epidemiological strategies applied to age-based restrictions versus horizontal lockdowns.

Bitsouni V, Gialelis N, Tsilidis V Infect Dis Model. 2024; 9(4):1301-1328.

PMID: 39309400 PMC: 11415861. DOI: 10.1016/j.idm.2024.07.002.


Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD).

Round J, Kirwin E, van Katwyk S, McCabe C Pharmacoeconomics. 2024; 42(11):1197-1208.

PMID: 39110389 DOI: 10.1007/s40273-024-01401-y.


Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis.

Chang E, Li H, Zheng W, Zhou L, Jia Y, Gu W Appl Health Econ Health Policy. 2024; 22(4):457-470.

PMID: 38598091 DOI: 10.1007/s40258-024-00880-6.


Impact of community mask mandates on SARS-CoV-2 transmission in Ontario after adjustment for differential testing by age and sex.

Peng A, Bosco S, Simmons A, Tuite A, Fisman D PNAS Nexus. 2024; 3(2):pgae065.

PMID: 38463611 PMC: 10923507. DOI: 10.1093/pnasnexus/pgae065.


Quantifying the economic gains associated with COVID-19 vaccination in the Canadian population: A cost-benefit analysis.

Tuite A, Ng V, Ximenes R, Diener A, Rafferty E, Ogden N Can Commun Dis Rep. 2024; 49(6):263-273.

PMID: 38440772 PMC: 10911688. DOI: 10.14745/ccdr.v49i06a03.


References
1.
Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

2.
Moreno-Perez O, Merino E, Leon-Ramirez J, Andres M, Ramos J, Arenas-Jimenez J . Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021; 82(3):378-383. PMC: 7802523. DOI: 10.1016/j.jinf.2021.01.004. View

3.
Emanuel E, Persad G, Kern A, Buchanan A, Fabre C, Halliday D . An ethical framework for global vaccine allocation. Science. 2020; 369(6509):1309-1312. PMC: 8691258. DOI: 10.1126/science.abe2803. View

4.
Poteet S, Craig B . QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets. Patient. 2021; 14(3):339-345. PMC: 8007385. DOI: 10.1007/s40271-021-00509-z. View

5.
Prem K, Cook A, Jit M . Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput Biol. 2017; 13(9):e1005697. PMC: 5609774. DOI: 10.1371/journal.pcbi.1005697. View